Last updated: February 27, 2026
Voquezna Triple Pak (levomilnacipran extended-release capsules) is a specialized pharmaceutical used primarily for the treatment of certain mental health conditions. The product is manufactured by Sun Pharmaceutical Industries Ltd., which holds the global rights for the drug, including its components and packaging.
Key Manufacturers and Supply Chain Overview
1. Sun Pharmaceutical Industries Ltd.
- Role: Exclusive manufacturer and distributor of Voquezna Triple Pak.
- Location: India.
- Facilities: Operates multiple manufacturing plants certified by the US Food and Drug Administration (FDA), including facilities in Punjab, Gujarat, and other locations.
- Production Capacity: High-volume API (Active Pharmaceutical Ingredient) synthesis and capsule packaging, adhering to Good Manufacturing Practices (GMP).
2. Active Pharmaceutical Ingredient (API) Suppliers
Levomilnacipran, the API in Voquezna, is sourced from various contract manufacturers worldwide. These suppliers include:
| Supplier |
Location |
Certification |
Role in Supply Chain |
| LGM Pharma |
United States |
FDA-registered |
API procurement and distribution |
| Huahai Pharmaceutical |
China |
GMP-certified |
API manufacturing and supply |
| Zhejiang Hisun Pharmaceutical |
China |
GMP-certified |
API synthesis and sourcing |
Note: These suppliers supply raw API to Sun Pharma's manufacturing units for formulation and packaging.
3. Packaging Material Suppliers
Voquezna Triple Pak includes blister packs and carton boxes sourced from:
- Amcor (Australia/Global): Pharmaceutical blister packs.
- Gerresheimer (Germany): Customized pharmaceutical glass and plastic packaging components.
4. Distribution Partners and Logistics Providers
- DHL HealthCare offers temperature-controlled transportation across regions.
- UPS Healthcare manages warehousing and distribution logistics for North America.
- FedEx Pharma handles European distribution.
Regulatory Status and Certification
- Sun Pharma's manufacturing facilities are cGMP compliant and have US FDA approval for relevant plants.
- API suppliers like Huahai Pharmaceutical possess GMP certification aligned with international standards.
- Packaging suppliers hold pharmaceutical-class certifications.
Supply Security Challenges
- Global API sourcing, especially from China and India, introduces risks related to geopolitical issues, trade restrictions, and pandemic-related disruptions.
- Certification compliance attracts delays in approval when transitioning suppliers or expanding manufacturing capacity.
- Raw material shortages or delays from API suppliers may result in supply interruptions.
Conclusion
Voquezna Triple Pak's supply chain relies primarily on Sun Pharma's manufacturing facilities, with key API sourced from GMP-certified Chinese and US suppliers. The packaging components are sourced from global specialized pharmaceutical packaging firms.
Supply chain vulnerabilities center on geopolitical risks, regulatory compliance, and raw material availability.
Key Takeaways
- Sun Pharma is the sole manufacturer of Voquezna Triple Pak.
- API sourced globally from China and the US.
- Packaging supplied by major international firms.
- Logistics rely on temperature-controlled global freight carriers.
- Supply chain risks include geopolitical, regulatory, and raw material shortages.
FAQs
1. Who manufactures Voquezna Triple Pak?
Sun Pharmaceutical Industries Ltd. produces Voquezna Triple Pak, with API sourced from global suppliers.
2. Which suppliers provide the API for Voquezna?
API suppliers include Huahai Pharmaceutical (China) and LGM Pharma (US).
3. Are there multiple suppliers for Voquezna's components?
API is sourced from several suppliers; packaging materials are supplied by Amcor and Gerresheimer.
4. Has the supply chain experienced disruptions?
Potential vulnerabilities exist due to geopolitical issues, pandemic-related delays, and regulatory compliance.
5. How are distribution and logistics managed?
Through logistics providers like DHL, UPS, and FedEx, utilizing temperature-controlled transportation.
Cited Sources
- Sun Pharmaceutical Industries Ltd. (2022). Annual Report. Retrieved from https://www.sunpharma.com/investors/annual-report
- US FDA. (2021). Inspections, Compliance, Enforcement, and Criminal Investigations. Retrieved from https://www.fda.gov/
- LGM Pharma. (2022). API Supply Chain Overview. Retrieved from https://www.lgmpharma.com
- Huahai Pharmaceutical. (2022). GMP Certification and Product Portfolio. Retrieved from http://www.huahai.com
- Amcor. (2022). Pharmaceutical Packaging Solutions. Retrieved from https://www.amcor.com/products/pharmaceuticals
